+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
All Ages
All Genders
ID05797662

Evaluating Propranolol for Treating Kaposi Sarcoma in Children and Adults An Open-Label Phase II Trial

Led by AIDS Malignancy Consortium · Updated on 2026-10-05

25

Participants Needed

6

Research Sites

25 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating propranolol as a treatment for Kaposi Sarcoma in both children and adults. This open-label, single-arm trial aims to assess the safety and effectiveness of propranolol for this condition. The study is sponsored by the AIDS Malignancy Consortium and focuses on participants with biopsy-confirmed, measurable Kaposi Sarcoma who do not require immediate chemotherapy. Participants will take propranolol twice daily for an initial 12-week period, with dosing based on age children 12 years or younger receive 3 mgkgday divided twice daily, while those older than 12 years take 120 mg twice daily. After 12 weeks, responses will be evaluated participants with a complete response continue treatment for an additional 6 weeks, and those with a partial response continue for 12 more weeks. Throughout the study, participants will be closely monitored for treatment responses and safety. Researchers will assess outcomes such as objective response rates, dose-limiting toxicities, and treatment-emergent adverse events at one year. The study includes evaluations of time to recurrence and progression for both children and adults. Total participation may last up to 24 weeks of treatment with follow-up assessments.

CONDITIONS

Brief Title

A Study of Propranolol to Treat Kaposi Sarcoma

Research Team

S

Shane McAllister, Md, Phd

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here